US Bancorp
TXG icon

US Bancorp’s 10x Genomics TXG Stock Holding History

US Bancorp’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Sell
6,081
-240
-4% -$6.29K ﹤0.01% 2019
2026
Q1 		$134K Sell
6,321
-29
-0.5% -$580 ﹤0.01% 2218
2025
Q4 		$104K Buy
6,350
+388
+7% +$5.86K ﹤0.01% 2346
2025
Q3 		$69.7K Sell
5,962
-24,575
-80% -$320K ﹤0.01% 2513
2025
Q2 		$354K Buy
30,537
+24,564
+411% +$224K ﹤0.01% 1693
2025
Q1 		$52.1K Buy
5,973
+4,532
+315% +$57.1K ﹤0.01% 2722
2024
Q4 		$20.7K Sell
1,441
-5,452
-79% -$86K ﹤0.01% 3139
2024
Q3 		$156K Sell
6,893
-1,724
-20% -$35.6K ﹤0.01% 2170
2024
Q2 		$168K Sell
8,617
-5,275
-38% -$138K ﹤0.01% 2085
2024
Q1 		$521K Sell
13,892
-1,320
-9% -$58K ﹤0.01% 1479
2023
Q4 		$851K Buy
15,212
+2,469
+19% +$107K ﹤0.01% 1202
2023
Q3 		$526K Sell
12,743
-567
-4% -$29.5K ﹤0.01% 1350
2023
Q2 		$743K Buy
13,310
+7,701
+137% +$417K ﹤0.01% 1198
2023
Q1 		$313K Buy
5,609
+726
+15% +$33.9K ﹤0.01% 1658
2022
Q4 		$178K Sell
4,883
-8,289
-63% -$271K ﹤0.01% 1925
2022
Q3 		$375K Sell
13,172
-1,330
-9% -$50.7K ﹤0.01% 1536
2022
Q2 		$657K Buy
14,502
+4,791
+49% +$249K ﹤0.01% 1291
2022
Q1 		$739K Buy
9,711
+2,753
+40% +$241K ﹤0.01% 1327
2021
Q4 		$1.04M Buy
6,958
+1,318
+23% +$202K ﹤0.01% 1185
2021
Q3 		$821K Buy
5,640
+397
+8% +$68.2K ﹤0.01% 1283
2021
Q2 		$1.03M Buy
5,243
+652
+14% +$118K ﹤0.01% 1186
2021
Q1 		$831K Buy
4,591
+4,391
+2,196% +$758K ﹤0.01% 1238
2020
Q4 		$28K Hold
200
– – ﹤0.01% 2762
2020
Q3 		$25K Hold
200
– – ﹤0.01% 2710
2020
Q2 		$18K Hold
200
– – ﹤0.01% 2875
2020
Q1 		$12K Hold
200
– – ﹤0.01% 2976
2019
Q4 		$15K Buy
+200
New +$12K ﹤0.01% 2987

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

US Bancorp's TXG Position: Q2 2026 in Review

US Bancorp reduced its 10x Genomics (TXG) stake by 3.8% in Q2 2026, selling an estimated $6.29K and leaving 6,081 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

US Bancorp first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.04M in Q4 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • US Bancorp held 6,081 shares of 10x Genomics worth $233K as of Q2 2026.
  • US Bancorp sold 240 10x Genomics shares in Q2 2026, an estimated $6.29K.
  • 10x Genomics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2019 holding.
  • US Bancorp first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • US Bancorp's 10x Genomics position peaked at $1.04M in Q4 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.